Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
COVID-19
SARS-CoV-2
bamlanivimab
monoclonal antibodies
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
30
04
2021
accepted:
12
05
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications. In this observational study we compared outpatients who received bamlanivimab monoclonal antibody from December 9, 2020 to March 3, 2021 to nontreated patients with a positive polymerase chain reaction or antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the same period who were eligible for monoclonal antibody treatment. The primary outcome was 28-day hospitalization or all-cause mortality, and the secondary outcome was hospitalization or emergency department visit without hospitalization. The risk-adjusted odds of study outcomes comparing bamlanivimab treated and untreated patients was determined using 1:5 propensity matching and multivariable logistic regression. Among 232 patients receiving bamlanivimab matched with 1160 comparator patients, the mean age was 67 years, 56% were female, and 196 (14%) of patients experienced hospitalization or mortality. After adjustment for propensity to receive treatment, bamlanivimab treatment was associated with a significantly reduced risk-adjusted odds of hospitalization or mortality within 28 days (odds ratio [OR], 0.40; 95% confidence interval [95% CI], 0.24-0.69; Bamlanivimab monoclonal antibody monotherapy was associated with reduced hospitalizations and mortality within 28 days among outpatients with mild to moderate COVID-19.Use of bamlanivimab monotherapy for outpatients with mild to moderate COVID-19 infection was associated with reductions in hospitalizations and mortality within 28 days. Benefit was strongest in those age 65 years or older.
Sections du résumé
BACKGROUND
BACKGROUND
Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications.
METHODS
METHODS
In this observational study we compared outpatients who received bamlanivimab monoclonal antibody from December 9, 2020 to March 3, 2021 to nontreated patients with a positive polymerase chain reaction or antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the same period who were eligible for monoclonal antibody treatment. The primary outcome was 28-day hospitalization or all-cause mortality, and the secondary outcome was hospitalization or emergency department visit without hospitalization. The risk-adjusted odds of study outcomes comparing bamlanivimab treated and untreated patients was determined using 1:5 propensity matching and multivariable logistic regression.
RESULTS
RESULTS
Among 232 patients receiving bamlanivimab matched with 1160 comparator patients, the mean age was 67 years, 56% were female, and 196 (14%) of patients experienced hospitalization or mortality. After adjustment for propensity to receive treatment, bamlanivimab treatment was associated with a significantly reduced risk-adjusted odds of hospitalization or mortality within 28 days (odds ratio [OR], 0.40; 95% confidence interval [95% CI], 0.24-0.69;
CONCLUSIONS
CONCLUSIONS
Bamlanivimab monoclonal antibody monotherapy was associated with reduced hospitalizations and mortality within 28 days among outpatients with mild to moderate COVID-19.Use of bamlanivimab monotherapy for outpatients with mild to moderate COVID-19 infection was associated with reductions in hospitalizations and mortality within 28 days. Benefit was strongest in those age 65 years or older.
Identifiants
pubmed: 34250192
doi: 10.1093/ofid/ofab254
pii: ofab254
pmc: PMC8241472
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab254Subventions
Organisme : NIAID NIH HHS
ID : K23 AI154546
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM119519
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
JAMA Surg. 2020 Jun 1;155(6):e200416
pubmed: 32267474
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Sci Transl Med. 2021 May 12;13(593):
pubmed: 33820835
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Clin Infect Dis. 2021 Apr 13;:
pubmed: 33846730